Citation, DOI, disclosures and article data
Citation:
Woolley M, Knipe H, F-18 DOPA. Reference article, Radiopaedia.org (Accessed on 18 Apr 2024) https://doi.org/10.53347/rID-88500
F-18 DOPA (3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine) is a PET radiotracer primarily used in the evaluation of neuropsychiatric diseases, movement disorders, and brain malignancies 1.
Production
L-DOPA is the nonproteinogenic amino acid precursor to dopamine with F-18 DOPA, in recent years, being synthesized by a nucleophilic substitution reaction.
Clinical uses
F-18 DOPA has mainly been used in the assessment of Parkinson disease 2, schizophrenia and gliomas. There is some emerging evidence that it may be used for pheochromocytoma, extra-adrenal abdominal paraganglioma as well as congenital hyperinsulinemia 3.
-
1. Pretze M, Wängler C, Wängler B. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. (2014) BioMed research international. 2014: 674063. doi:10.1155/2014/674063 - Pubmed
-
2. Ibrahim N, Kusmirek J, Struck AF, Floberg JM, Perlman SB, Gallagher C, Hall LT. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. (2016) American journal of nuclear medicine and molecular imaging. 6 (1): 102-9. Pubmed
-
3. Cristina Nanni, Stefano Fanti, Domenico Rubello. 18F-DOPA PET and PET/CT. (2007) Journal of Nuclear Medicine. 48 (10): 1577. doi:10.2967/jnumed.107.041947 - Pubmed
Promoted articles (advertising)